サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1412619

免疫調節剤市場：製品別、用途別-2024-2030年の世界予測

Immunomodulators Market by Product (Immunostimulants, Immunosuppressants), Application (HIV, Oncology, Respiratory) - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 183 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
免疫調節剤市場：製品別、用途別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 183 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

免疫調節剤市場規模は2023年に1,987億5,000万米ドルと推定され、2024年には2,064億6,000万米ドルに達すると予測され、CAGR 3.81%で2030年には2,582億6,000万米ドルに達すると予測されます。

世界の免疫調節剤市場

主な市場の統計
基準年[2023］ 1,987億5,000万米ドル
予測年[2024] 2,064億6,000万米ドル
予測年 [2030] 2,582億6,000万米ドル
CAGR（%） 3.81%
免疫調節剤 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは免疫調節剤市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、免疫調節剤市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-免疫調節剤市場の市場規模および予測は？

2-免疫調節剤市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-免疫調節剤市場における技術動向と規制の枠組みは？

4-免疫調節剤市場における主要ベンダーの市場シェアは？

5-免疫調節剤市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 自己免疫疾患の有病率の上昇
      • 炎症性腸疾患に対する意識の向上
      • 強力な医薬品パイプラインポートフォリオの存在
    • 抑制要因
      • 免疫調節剤薬物の副作用と製品の高価格
    • 機会
      • 免疫調節剤の臨床研究と研究開発活動の数が増加
      • 炎症性腸疾患に対する免疫調節療法の進歩
    • 課題
      • 免疫調節剤医薬品の承認に関する規制ポリシー
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 免疫調節剤市場：製品別

  • 免疫賦活剤
    • 抗体
    • ワクチン
  • 免疫抑制剤
    • 抗体
    • 代謝拮抗物質
    • カルシニューリン阻害剤
    • 糖質コルチコイド

第7章 免疫調節剤市場：用途別

  • HIV
  • 腫瘍学
  • 呼吸器系

第8章 南北アメリカの免疫調節剤市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の免疫調節剤市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカの免疫調節剤市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第12章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Abbott Laboratories
    • AbbVie Inc.
    • Amgen Inc.
    • Arix Bioscience PLC
    • Bayer AG
    • BioNTech SE
    • Bristol Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline PLC
    • Horizon Therapeutics PLC
    • InDex Pharmaceuticals Holding AB
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Pfizer Inc.
  • 主要な製品ポートフォリオ

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. IMMUNOMODULATORS MARKET RESEARCH PROCESS
  • FIGURE 2. IMMUNOMODULATORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. IMMUNOMODULATORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. IMMUNOMODULATORS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. IMMUNOMODULATORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. IMMUNOMODULATORS MARKET DYNAMICS
  • FIGURE 7. IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES IMMUNOMODULATORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES IMMUNOMODULATORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. IMMUNOMODULATORS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. IMMUNOMODULATORS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. IMMUNOMODULATORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. IMMUNOMODULATORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 6. IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 8. IMMUNOMODULATORS MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. IMMUNOMODULATORS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 12. IMMUNOMODULATORS MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. IMMUNOMODULATORS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. IMMUNOMODULATORS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. IMMUNOMODULATORS MARKET SIZE, BY GLUCOCORTICOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. IMMUNOMODULATORS MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. IMMUNOMODULATORS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. IMMUNOMODULATORS MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES IMMUNOMODULATORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM IMMUNOMODULATORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSTIMULANTS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM IMMUNOMODULATORS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM IMMUNOMODULATORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. IMMUNOMODULATORS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 189. IMMUNOMODULATORS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. IMMUNOMODULATORS MARKET LICENSE & PRICING
目次
Product Code: MRR-ED54C46E8160

[183 Pages Report] The Immunomodulators Market size was estimated at USD 198.75 billion in 2023 and expected to reach USD 206.46 billion in 2024, at a CAGR 3.81% to reach USD 258.26 billion by 2030.

Global Immunomodulators Market

KEY MARKET STATISTICS
Base Year [2023] USD 198.75 billion
Estimated Year [2024] USD 206.46 billion
Forecast Year [2030] USD 258.26 billion
CAGR (%) 3.81%
Immunomodulators Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Immunomodulators Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Immunomodulators Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Immunomodulators Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., Arix Bioscience PLC, Bayer AG, BioNTech SE, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Horizon Therapeutics PLC, InDex Pharmaceuticals Holding AB, Johnson & Johnson Services, Inc., Merck & Co., Inc., and Pfizer Inc..

Market Segmentation & Coverage

This research report categorizes the Immunomodulators Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Immunostimulants
      • Antibodies
      • Vaccines
    • Immunosuppressants
      • Antibodies
      • Antimetabolites
      • Calcineurin Inhibitors
      • Glucocorticoids
  • Application
    • HIV
    • Oncology
    • Respiratory
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Immunomodulators Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Immunomodulators Market?

3. What are the technology trends and regulatory frameworks in the Immunomodulators Market?

4. What is the market share of the leading vendors in the Immunomodulators Market?

5. Which modes and strategic moves are suitable for entering the Immunomodulators Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Immunomodulators Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence rate of autoimmune diseases
      • 5.1.1.2. Increasing awareness about inflammatory bowel diseases
      • 5.1.1.3. Presence of strong drug pipeline portfolio
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse effect of immunomodulators drugs and high cost of the products
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing number of clinical studies and R&D activities of immunomodulators
      • 5.1.3.2. Advancement of immunomodulatory therapy for inflammatory bowel disease
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory policies for the approval of the Immunomodulators medications
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Immunomodulators Market, by Product

  • 6.1. Introduction
  • 6.2. Immunostimulants
    • 6.3.1. Antibodies
    • 6.3.2. Vaccines
  • 6.3. Immunosuppressants
    • 6.4.1. Antibodies
    • 6.4.2. Antimetabolites
    • 6.4.3. Calcineurin Inhibitors
    • 6.4.4. Glucocorticoids

7. Immunomodulators Market, by Application

  • 7.1. Introduction
  • 7.2. HIV
  • 7.3. Oncology
  • 7.4. Respiratory

8. Americas Immunomodulators Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Immunomodulators Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Immunomodulators Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. Abbott Laboratories
    • 12.1.2. AbbVie Inc.
    • 12.1.3. Amgen Inc.
    • 12.1.4. Arix Bioscience PLC
    • 12.1.5. Bayer AG
    • 12.1.6. BioNTech SE
    • 12.1.7. Bristol Myers Squibb Company
    • 12.1.8. Eli Lilly and Company
    • 12.1.9. F. Hoffmann-La Roche Ltd.
    • 12.1.10. GlaxoSmithKline PLC
    • 12.1.11. Horizon Therapeutics PLC
    • 12.1.12. InDex Pharmaceuticals Holding AB
    • 12.1.13. Johnson & Johnson Services, Inc.
    • 12.1.14. Merck & Co., Inc.
    • 12.1.15. Pfizer Inc.
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing